FG001
Sponsors
Copenhagen University Hospital, Rigshospitalet, FluoGuide A/S
Conditions
GliomaHigh-Grade Glioma (WHO III-IV)MeningiomaOral Squamous Cell Carcinoma with neck metastasesOropharyngeal Squamous Cell Carcinoma
Phase 2
An open-label, non-randomized, single dose, phase II trial of FG001 (an optical imaging agent) for localization of Meningiomas or presumed Low- Grade Gliomas scheduled for neurosurgery.
Not yet recruitingCTIS2024-520426-11-00
Target: 40Updated: 2025-01-29
FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma
Not yet recruitingNCT07609472
Start: 2026-06-30End: 2028-07-31Target: 76Updated: 2026-05-29
An open-label, non-randomized, single center, single dose, exploratory phase II trial of FG001 (an imaging agent) in combination with transoral robotic surgery for oropharyngeal squamous cell carcinoma and neck dissection surgery for oral squamous cell carcinoma with regional lymph node metastases
Not yet recruitingCTIS2025-522845-23-00
Target: 40Updated: 2026-06-08